CSTONE PHARMA-B (02616.HK): Shares Added to Stock Connect Eligible List, Effective 7 September 2026

NewTimeSpace News: On 7 September 2026, CStone Pharmaceuticals (stock code: 02616) announced in a voluntary filing that the company's shares have been added to the Stock Connect eligible securities list, with effect from 7 September 2026. Qualified mainland Chinese investors will be able to trade the shares directly through the Stock Connect mechanism.

Dr. Yang Jianxin, CEO, R&D president and executive director, stated that the inclusion reflects market recognition of the company's innovative capability and long-term potential, and is expected to broaden the investor base and enhance secondary-market liquidity.

The announcement highlighted core pipeline assets including the PD-1/VEGF/CTLA-4 trispecific antibody CS2009, whose global Phase I/II trial is advancing with the company expecting to initiate the first global Phase III registrational trial before the end of 2026, and the self-developed EGFR/HER3 bispecific ADC CS5007, whose global Phase I trial has been initiated in both China and Australia.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.